Smoldering multiple myeloma current treatment algorithms.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
05 09 2022
05 09 2022
Historique:
received:
06
07
2022
accepted:
10
08
2022
revised:
03
08
2022
entrez:
5
9
2022
pubmed:
6
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Smoldering multiple myeloma (SMM) is an asymptomatic condition that occupies a space between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) along the spectrum of clonal plasma cell proliferative disorders. It is not a biologic intermediate stage between MGUS and MM, but rather represents a heterogeneous clinically defined condition in which some patients (approximately two-thirds) have MGUS (pre-malignancy), and some (approximately one-third) have MM (biologic malignancy). Unfortunately, no single pathologic or molecular feature can reliably distinguish these two groups of patients. For purposes of practice and clinical trials, specific risk factors are used to identify patients with SMM in whom malignant transformation has already likely occurred (high risk SMM). Patients with newly diagnosed high risk SMM should be offered therapy with lenalidomide or lenalidomide plus dexamethasone (Rd) for 2 years, or enrollment in clinical trials. Patients with low risk SMM should be observed without therapy every 3-4 months.
Identifiants
pubmed: 36064707
doi: 10.1038/s41408-022-00719-0
pii: 10.1038/s41408-022-00719-0
pmc: PMC9445066
doi:
Substances chimiques
Biological Products
0
Lenalidomide
F0P408N6V4
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
129Subventions
Organisme : NCI NIH HHS
ID : P50 CA186781
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA168762
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
J Clin Oncol. 2013 Dec 1;31(34):4325-32
pubmed: 24145347
Lancet Oncol. 2016 Aug;17(8):1127-1136
pubmed: 27402145
Mayo Clin Proc. 2013 Nov;88(11):1284-93
pubmed: 24182705
J Clin Oncol. 2010 Mar 20;28(9):1606-10
pubmed: 20177023
Blood. 2014 Jan 2;123(1):78-85
pubmed: 24144643
Blood Cancer J. 2021 May 17;11(5):94
pubmed: 34001889
Leukemia. 2018 Aug;32(8):1811-1815
pubmed: 29568092
Blood Cancer J. 2018 Jun 12;8(6):59
pubmed: 29895887
Am J Hematol. 2012 May;87(5):453-4
pubmed: 22488611
N Engl J Med. 2013 Oct 31;369(18):1763
pubmed: 24171528
Leukemia. 2018 Jun;32(6):1427-1434
pubmed: 29463830
N Engl J Med. 2013 Oct 31;369(18):1764-5
pubmed: 24171526
N Engl J Med. 2007 Jun 21;356(25):2582-90
pubmed: 17582068
J Clin Oncol. 2003 Jan 1;21(1):16-9
pubmed: 12506164
Leukemia. 2013 Mar;27(3):680-5
pubmed: 22902364
N Engl J Med. 2006 Mar 30;354(13):1362-9
pubmed: 16571879
Lancet Oncol. 2019 Jun;20(6):e302-e312
pubmed: 31162104
Blood. 2009 May 28;113(22):5412-7
pubmed: 19179464
Leukemia. 2016 Feb;30(2):417-22
pubmed: 26490489
Leukemia. 2013 Aug;27(8):1738-44
pubmed: 23515097
Leukemia. 2013 Apr;27(4):941-6
pubmed: 23183428
Leuk Lymphoma. 2011 May;52(5):771-5
pubmed: 21299465
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Blood. 2009 May 28;113(22):5418-22
pubmed: 19234139
J Clin Oncol. 2020 Jul 20;38(21):2363-2365
pubmed: 32463739
Blood. 2008 Jan 15;111(2):785-9
pubmed: 17942755
Mayo Clin Proc. 2017 May;92(5):838-850
pubmed: 28473042
N Engl J Med. 2018 Jan 18;378(3):241-249
pubmed: 29342381
J Clin Oncol. 2020 Apr 10;38(11):1126-1137
pubmed: 31652094
Blood. 2000 Sep 15;96(6):2037-44
pubmed: 10979944
Blood Cancer J. 2016 Jul 29;6(7):e454
pubmed: 27471870
Leukemia. 2014 Sep;28(9):1902-8
pubmed: 24535407
Br J Cancer. 1996 May;73(9):1101-7
pubmed: 8624271
N Engl J Med. 2002 Feb 21;346(8):564-9
pubmed: 11856795
Eur J Haematol. 1993 Feb;50(2):95-102
pubmed: 8440364
Haematologica. 2014 Jun;99(6):984-96
pubmed: 24658815
Br J Cancer. 2000 Apr;82(7):1254-60
pubmed: 10755397
Am J Hematol. 2020 May;95(5):548-567
pubmed: 32212178
Blood Cancer J. 2020 Oct 16;10(10):102
pubmed: 33067414
Leukemia. 2010 Jun;24(6):1121-7
pubmed: 20410922
Cancer. 2008 Oct 1;113(7):1588-95
pubmed: 18683218
Br J Haematol. 2003 Nov;123(4):631-6
pubmed: 14616966
Lancet. 2010 May 15;375(9727):1721-8
pubmed: 20472173
Blood. 2007 Oct 1;110(7):2586-92
pubmed: 17576818
N Engl J Med. 2013 Oct 31;369(18):1762-3
pubmed: 24171527
N Engl J Med. 2013 Aug 1;369(5):438-47
pubmed: 23902483
Leukemia. 2022 May;36(5):1429-1431
pubmed: 35190659
Leukemia. 2003 Apr;17(4):775-9
pubmed: 12682636
Leukemia. 2013 Jan;27(1):220-5
pubmed: 22902362
Am J Med. 1993 Jan;94(1):57-61
pubmed: 8420300
Blood. 2015 May 14;125(20):3069-75
pubmed: 25838344
Blood Cancer J. 2019 Dec 13;9(12):102
pubmed: 31836698